BIND Biosciences Granted Five U.S. Patents for its Medicinal Nanoengineering® Platform and Lead Drug Candidate, BIND-014

Total of Ten U.S. Patents Issued to Company in 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins^TM, announced today that the United States Patent and Trademark Office (USPTO) has recently granted five U.S. patents to the Company, bringing the total patents issued to the Company in 2012 to ten. These patents cover BIND-014, the Company’s lead Accurin product candidate in Phase 1 clinical development for the treatment of solid tumor cancers, and BIND’s Medicinal Nanoengineering^® platform, which enables the design, engineering and manufacturing of Accurins with unprecedented control over drug properties to maximize trafficking to disease sites.

“Drug Loaded Polymeric Particles and Methods of Making the Same”

The newly-issued U.S. patents include the following:

• Patent #8,273,363 entitled “Cancer Cell Targeting Using Nanoparticles” relates to BIND-014 and its PSMA targeting ligand
• Patent #8,293,276 entitled “Drug Loaded Polymeric Particles and Methods of Making the Same” relates to BIND’s nanoemulsion manufacturing process used to make Accurins
• Patent #8,318,208 entitled “Drug Loaded Polymeric Particles and Methods of Making the Same” relates to the polymer composition of BIND-014 and BIND’s Medicinal Nanoengineering platform
• Patent #8,318,211 entitled “Therapeutic Polymeric Nanoparticles comprising Vinca Alkaloids” relates to Accurins of vinca alkaloids
• Patent #8,323,698 entitled “Polymers for Functional Particles” relates to targeted nanoparticles produced by a single step self-assembly process.

“The issuance of these five additional patents in 2012 further validates the innovative nature of our platform technology and the proprietary methods we use to produce our products. BIND’s patent estate now consists of more than 50 patent families, and we expect additional patent issuances in 2013 which will further strengthen our broad patent estate,” said Scott Minick, CEO of BIND.

About BIND Biosciences

BIND Biosciences is a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins^TM. BIND’s Medicinal Nanoengineering^® platform enables the design, engineering and manufacturing of Accurins with unprecedented control over drug properties to maximize trafficking to disease sites, dramatically enhancing efficacy while minimizing toxicities.

BIND is developing a pipeline of novel Accurins that hold extraordinary potential to become best-in-class drugs and improve patient outcomes in the areas of oncology, inflammatory diseases and cardiovascular disorders. BIND's lead product candidate, BIND-014, is currently in Phase 1 clinical testing in cancer patients and is designed to selectively target a surface protein upregulated in a broad range of solid tumors. BIND also develops Accurins in collaboration with pharmaceutical and biotechnology partners to enable promising pipeline candidates to achieve their full potential and to utilize selective targeting to transform the performance of important existing drug products.

BIND is backed by leading investors, Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension, DHK Investments, EndeavourVision and Rusnano. BIND was founded on proprietary technology from the laboratories of two leaders in the field of nanomedicine, Professors Robert Langer, David H. Koch Institute Professor of the Massachusetts Institute of Technology (MIT) and Omid Farokhzad, Associate Professor of Harvard Medical School. For more information, please visit the company's web site at www.bindbio.com.